CNN: Netanyahu seeks emergency meeting with Trump amid mounting tensions over negotiations with Iran
6 minutes agoBioNTech, Johnson's Modern are working on the new vaccine against Omitron
Periskopi(5 years ago)
(5 years ago)BioNtech companies, Moderna, Johnson and Johnson (J&J) are working on vaccines that especially target the new type of coronary omicro in the event existing vaccines are not effective against the new version, it is said today's announcement of these companies. The showing of the new omitron variant has caused global reactions because all are [...]
The showing of the new omitron variant has triggered global reactions because everyone is concerned that the new type could spread quickly even among the vaccines, Reuters reports.
As a result, travel restrictions and other epidemiological restrictions worldwide have been reintroduced.
From BioNTech came the confirmation that the company, in co-operation with Pfizer partners, started working on a vaccine adapted to the omitron variant.
Meanwhile, Moderna's executive chief, Stefan Bansel, told CNBC that the handover of the new vaccine could last several months, announcing that after nearly two weeks, the degree to which existing vaccines are effective against the omitron variant should be known.
J&J is also assessing the effectiveness of the existing vaccine against COVID-19 in the case of Omitron version infection and is at the same time looking for a specific vaccine.
“We have started work on drafting and developing a new vaccine against omicron and will advance rapidly and start clinical studies if necessary,” said Matai Mamen, head of the J&J Global Research Department.
An expert on infectious diseases from South Africa said that omitron, a variant of the coronary, seems to be more transmitted than previous variants, even to people with immunity earned by vaccine or after an earlier infection.
